However, severe CRS cases, particularly those complicated by secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), may be refractory to IL-6 inhibition and require more aggressive immunosuppressive interventions, including chemotherapy (1, 14, 15). This evidence concerns the gene IL6 and hemophagocytic syndrome.